Simulations Plus, Inc.

Equities

SLP

US8292141053

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
45.45 ^USD	+1.70%		+1.00%	+1.56%

Apr. 17	InnoGI Technologies and Simulations Plus Combine Forces to Offer Next-Level Modeling Solutions for the Prediction of Oral Drug Performance	CI
Apr. 04	Sector Update: Health Care Stocks Slump Late Afternoon	MT

Simulations Plus, Inc. Provides Earnings Guidance for the Fiscal Year 2024

April 03, 2024 at 04:07 pm EDT

Simulations Plus, Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expected revenue to be $66 million - $69 million (10 - 15%) and Diluted earnings per share to be $0.66 - $0.68 (35 - 39%).

Latest news about Simulations Plus, Inc.

InnoGI Technologies and Simulations Plus Combine Forces to Offer Next-Level Modeling Solutions for the Prediction of Oral Drug Performance	Apr. 17	CI
Sector Update: Health Care Stocks Slump Late Afternoon	Apr. 04	MT
Simulations Plus Says FDA Renews DILIsym Software Licenses	Apr. 04	MT
Sector Update: Tech Stocks Advance Premarket Thursday	Apr. 04	MT
Simulations Plus, Inc. Announces U.S. FDA Renews DILIsym Software Licenses	Apr. 04	CI
Sector Update: Tech	Apr. 04	MT
Simulations Plus Fiscal Q2 Earnings Beat as Revenue Rises; Maintains Full-Year Outlook; Shares Advance Premarket	Apr. 04	MT
Simulations Plus Fiscal Q2 Net Income Is Unchanged, Revenue Rises; FY Outlook Maintained; Shares Jump After Hours	Apr. 03	MT
Simulations Plus to Seek M&A	Apr. 03	CI
Transcript : Simulations Plus, Inc., Q2 2024 Earnings Call, Apr 03, 2024	Apr. 03
(SLP) SIMULATIONS PLUS Expects Fiscal Year 2024 EPS Range $0.66 - $0.68	Apr. 03	MT
Earnings Flash (SLP) SIMULATIONS PLUS Posts Q2 Revenue $18.3M, vs. Street Est of $17.3M	Apr. 03	MT
Earnings Flash (SLP) SIMULATIONS PLUS Posts Q2 EPS $0.20, vs. Street Est of $0.18	Apr. 03	MT
Simulations Plus, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	Apr. 03	CI
Simulations Plus, Inc. Declares a Cash Dividend, Payable on May 6, 2024	Apr. 03	CI
Simulations Plus, Inc. Provides Earnings Guidance for the Fiscal Year 2024	Apr. 03	CI
Simulations Plus Insider Sold Shares Worth $798,867, According to a Recent SEC Filing	Apr. 02	MT
Simulations Plus Insider Sold Shares Worth $828,240, According to a Recent SEC Filing	Mar. 05	MT
Simulations Plus, Inc. Extends Collaboration with Major Toxicology Research Agency	Feb. 15	CI
Simulations Plus, Inc. Releases GastroPlus Version 9.9	Jan. 30	CI
Simulations Plus Insider Sold Shares Worth $889,200, According to a Recent SEC Filing	Jan. 05	MT
Tranche Update on Simulations Plus, Inc.'s Equity Buyback Plan announced on January 4, 2023.	Jan. 05	CI
(SLP) SIMULATIONS PLUS Forecasts Fiscal Year 2024 EPS Range $0.66 - $0.68	Jan. 03	MT
Earnings Flash (SLP) SIMULATIONS PLUS Reports Q1 Revenue $14.5M, vs. Street Est of $13.9M	Jan. 03	MT
Simulations Plus, Inc. Declares Cash Dividend, Payable on February 5, 2024	Jan. 03	CI

Chart Simulations Plus, Inc.

Duration

Period

More charts

Company Profile

Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-07-09 - Q3 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Simulations Plus, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

44.69 USD

Average target price

53.67 USD

Spread / Average Target

+20.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

	1st Jan change	Capi.
SIMULATIONS PLUS, INC.	+1.56%	893M
VEEVA SYSTEMS INC.	+4.71%	32.47B
PRO MEDICUS LIMITED	+16.51%	7.45B
SECTRA AB	+23.49%	3.89B
EVOLENT HEALTH, INC.	-15.80%	3.17B
OMNICELL, INC.	-27.19%	1.28B
LUNIT INC.	-33.58%	1.09B
B-SOFT CO.,LTD.	-33.74%	902M
VERADIGM INC.	-23.93%	857M
SURGICAL SCIENCE SWEDEN AB	-14.74%	693M

Medical Software & Technology Services